Trials / Completed
CompletedNCT04952545
Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
A Phase 1 Study to Determine the Safety, Tolerability, and Pharmacokinetics of ALXN2050 in Healthy Participants of Japanese Descent
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1 bridging study being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALXN2050 after both single- and multiple-dosing in healthy participants of Japanese descent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN2050 | Oral tablet. |
| DRUG | Placebo | Oral tablet. |
Timeline
- Start date
- 2021-07-09
- Primary completion
- 2021-09-07
- Completion
- 2021-09-07
- First posted
- 2021-07-07
- Last updated
- 2022-12-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04952545. Inclusion in this directory is not an endorsement.